Haichang Bio Recognized as National-Level 'Specialized, Sophisticated, and Innovative' Little Giant Enterprise, Spearheading Biopharmaceutical Innovation
Haichang Biotech
Innovative Formulation Developer
On September 2, the Ministry of Industry and Information Technology of China announced the "List of the Sixth Batch of Specialized,精细化, Unique, and Innovative 'Little Giant' Enterprises and the Third Batch of Re-examined 'Little Giant' Enterprises for Public Disclosure." Haichang Biotech (Zhejiang Haichang Biomedical Technology Co., Ltd.) was successfully selected. This honor is not only authoritative recognition of Haichang Biotech's achievements in research, production, and clinical transformation in the fields of nucleic acid drugs and high-end complex injectables, but also a high affirmation of its role as a core driving force and key player in the innovation and upgrading process of China's biopharmaceutical industry.
Since its establishment, Haichang Biotech has been committed to advancing the frontiers of research and development in high-end complex injectables and nucleic acid drugs. The company focuses on revolutionary breakthroughs in delivery technologies and the continuous refinement of drug development processes and production techniques. Haichang Biotech boasts an elite team of internationally renowned scientists and industry veterans, leading the wave of technological innovation with a global perspective. They meticulously manage risks at every stage of drug development and regulatory submission, successfully overcoming numerous technical barriers in translating high-end complex injectables and nucleic acid drugs from fundamental laboratory research to clinical applications, thereby contributing to the advancement of the biopharmaceutical field.
About Haichang Biotech
Haichang Biotech, located in the China Medical Valley in Hangzhou, is a national high-tech enterprise specializing in the innovative development of biopharmaceutical technologies. With independent innovation capabilities and a global intellectual property layout, the company focuses on the core values of "sharing, progress, truth-seeking, and pragmatism." Centered on the development and industrialization of drug delivery systems, Haichang Biotech concentrates on the development of nucleic acid innovative drugs such as small nucleic acid drugs, mRNA vaccines, and complex injectables. Currently, its injectable paclitaxel (albumin-bound) has been approved for marketing in China and the EU, with registration applications ongoing in multiple countries along the Belt and Road. The small nucleic acid new drug HC0301 has received dual approval from the FDA and NMPA and is undergoing global multi-center Phase II clinical trials. The mRNA COVID-19 vaccine booster has been approved by the FDA for clinical trials, making it the first Chinese-produced mRNA vaccine product to receive U.S. clinical approval. Its product pipeline covers areas including infectious disease prevention, cancer immunotherapy, anti-cancer treatments, and pain management.
